COVID-19's hidden toll: fungal infections rise in transplant patients
NCT ID NCT06900114
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked back at 60 adult blood cancer patients who had stem cell transplants and later developed a rare fungal infection called mucormycosis. Researchers compared cases before COVID-19 (2015-2020) to during the pandemic (2020-2024) to see if the virus, new tests, or new drugs changed how often the infection occurred, how it was diagnosed, or how it was treated. The goal is to improve future care for these vulnerable patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could help doctors better manage and treat mucormycosis in stem cell transplant patients, potentially improving survival and reducing costs.
What could go wrong
This is a small, single-center retrospective study, so findings may not apply to other hospitals or countries. It only observes past data, so it cannot prove what caused any changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China